Top

Published in:

01-01-2019 | Original Article

African-Americans and Indigenous Peoples Have Increased Burden of Diseases of the Exocrine Pancreas: A Systematic Review and Meta-Analysis

Authors: Aya Cervantes, Ellen K. Waymouth, Maxim S. Petrov

Published in: Digestive Diseases and Sciences | Issue 1/2019

Abstract

Ethnic health disparity is a well-acknowledged issue in many disease settings, but not diseases of the exocrine pancreas. A systematic review and meta-analysis was conducted to explore the race- and ethnicity-specific burden of diseases of the exocrine pancreas. Studies that compared health-related endpoints between two or more ethnicities were eligible for inclusion. Proportion meta-analyses were conducted to compare burden between groups. A total of 42 studies (24 on pancreatic cancer, 17 on pancreatitis, and one on pancreatic cyst) were included in the systematic review, of which 19 studies were suitable for meta-analyses. The incidence of pancreatic cancer was 1.4-fold higher among African–Americans, while the incidence of acute pancreatitis was 4.8-fold higher among an indigenous population (New Zealand Māori) compared with Caucasians. The prevalence of post-pancreatitis diabetes mellitus was up to 3.0-fold higher among certain ethnicities, including Asians, Pacific Islanders, and indigenous populations compared with Caucasians. The burden of diseases of the exocrine pancreas differs between ethnicities, with African-Americans and certain indigenous populations being at the greatest risk of developing these diseases. Development of race- and ethnicity-specific screening as well as protocols for lifestyle modifications may need to be considered with a view to reducing the disparities in burden of diseases of the exocrine pancreas.

Xiao AY, Tan ML, Wu LM, et al. Global incidence and mortality of pancreatic diseases: a systematic review, meta-analysis, and meta-regression of population-based cohort studies. Lancet Gastroenterol Hepatol. 2016;1:45–55.PubMed

Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.PubMed

Liberal R, Vergani D. Effect of ethnicity on the clinical presentation and outcome of autoimmune hepatitis. Expert Rev Gastroenterol Hepatol. 2012;6:267–269.PubMed

Alberts SR, Kelly JJ, Ashokkumar R, et al. Occurrence of pancreatic, biliary tract, and gallbladder cancers in Alaska Native people, 1973–2007. Int J Circumpolar Health. 2012;71:17521.PubMed

Wilcox CM, Sandhu BS, Singh V, et al. Racial differences in the clinical profile, causes, and outcome of chronic pancreatitis. Am J Gastroenterol. 2016;111:1488–1496.PubMedPubMedCentral

Hall TC, Garcea G, Webb MA, et al. The socio-economic impact of chronic pancreatitis: a systematic review. J Eval Clin Pract. 2014;20:203–207.PubMed

Pendharkar SA, Mathew J, Petrov MS. Age- and sex-specific prevalence of diabetes associated with diseases of the exocrine pancreas: a population-based study. Dig Liver Dis. 2017;49:540–544.PubMed

Korc M, Jeon CY, Edderkaoui M, Pandol SJ, Petrov MS. Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC). Tobacco and alcohol as risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol. 2017;31:529–536.PubMedPubMedCentral

Rich NE, Oji S, Mufti AR, et al. Racial and ethnic disparities in non-alcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16:198–210.e2.PubMed

10.

Nguyen GC, Thuluvath PJ. Racial disparity in liver disease: biological, cultural, or socioeconomic factors. Hepatology. 2008;47:1058–1066.PubMed

11.

Hou JK, El-Serag H, Thirumurthi S. Distribution and manifestations of inflammatory bowel disease in asians, hispanics, and African Americans: a systematic review. Am J Gastroenterol. 2009;104:2100–2109.PubMed

12.

Bopanna S, Ananthakrishnan AN, Kedia S, et al. Risk of colorectal cancer in Asian patients with ulcerative colitis: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2:269–276.PubMedPubMedCentral

13.

Yang JD, Mohamed EA, Aziz AOA, et al. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. Lancet Gastroenterol Hepatol. 2017;2:103–111.PubMed

14.

Guy J, Yee HF Jr. Health disparities in liver disease: time to take notice and take action. Hepatology. 2009;50:309–313.PubMedPubMedCentral

15.

Ashktorab H, Kupfer SS, Brim H, et al. Racial disparity in gastrointestinal cancer risk. Gastroenterology. 2017;153:910–923.PubMedPubMedCentral

16.

Yang AL, Vadhavkar S, Singh G, et al. Epidemiology of alcohol-related liver and pancreatic disease in the United States. Arch Intern Med. 2008;168:649.PubMed

17.

Brotherton L, Welton M, Robb SW. Racial disparities of pancreatic cancer in Georgia: a county-wide comparison of incidence and mortality across the state, 2000–2011. Cancer Med. 2016;5:100–110.PubMed

18.

Chang KJ, Parasher G, Christie C, et al. Risk of pancreatic adenocarcinoma. Cancer. 2005;103:349–357.PubMed

19.

Pendharkar SA, Mathew J, Zhao J, et al. Ethnic and geographic variations in the incidence of pancreatitis and post-pancreatitis diabetes mellitus in New Zealand: a nationwide population-based study. N Z Med J. 2017;130:55–68.PubMed

20.

White MC, Espey DK, Swan J, et al. Disparities in cancer mortality and incidence among American Indians and Alaska Natives in the United States. Am J Public Health. 2014;104:S377–S387.PubMedPubMedCentral

21.

Wells G, Shea B, O’connell D, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Health Institute; (1996–2006).

22.

McPheeters ML, Kripalani S, Peterson NB, et al. Closing the gap: revisiting the state of science (vol. 3: quality improvement interventions to address health disparities). Evid Rep Technol Assess. 2012;208:1–475.

23.

Arnold LD, Patel AV, Yan Y, et al. Are racial disparities in pancreatic cancer explained by smoking and overweight/obesity? Cancer Epidemiol Biomark Prev. 2009;18:2397–2405.

24.

Beeghly-Fadiel A, Luu HN, Du L, et al. Early onset pancreatic malignancies: clinical characteristics and survival associations. Int J Cancer. 2016;139:2169–2177.PubMed

25.

Coughlin SS, Calle EE, Patel AV, et al. Predictors of pancreatic cancer mortality among a large cohort of United States adults. Cancer Causes Control. 2000;11:915–923.PubMed

26.

Eldridge RC, Gapstur SM, Newton CC, et al. Jewish ethnicity and pancreatic cancer mortality in a large U.S. cohort. Cancer Epidemiol Biomark Prev. 2011;20:691–698.

27.

Eloubeidi MA, Desmond RA, Wilcox CM, et al. Prognostic factors for survival in pancreatic cancer: a population-based study. Am J Surg. 2006;192:322–329.PubMed

28.

Fesinmeyer MD, Austin MA, Li CI, et al. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomark Prev. 2005;14:1766–1773.

29.

Kuo EJ, Salem RR. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size. Ann Surg Oncol. 2013;20:2815–2821.PubMed

30.

Lee S, Reha JL, Tzeng C-WD, et al. Race does not impact pancreatic cancer treatment and survival in an equal access federal health care system. Ann Surg Oncol. 2013;20:4073–4079.PubMed

31.

Longnecker DS, Karagas MR, Tosteson TD, et al. Racial differences in pancreatic cancer: comparison of survival and histologic types of pancreatic carcinoma in Asians, blacks, and whites in the United States. Pancreas. 2000;21:338–343.PubMed

32.

Ma J, Siegel R, Jemal A. Pancreatic cancer death rates by race among US men and women, 1970–2009. J Natl Cancer Inst. 2013;105:1694–1700.PubMed

33.

Mishra MV, Keith SW, Shen X, et al. Primary pancreatic lymphoma. Am J Clin Oncol. 2013;36:38–43.PubMed

34.

Phillips ARJ, Lawes CMM, Cooper GJS, et al. Ethnic disparity of pancreatic cancer in New Zealand. Int J Gastrointest Cancer. 2002;31:137–146.PubMed

35.

Saif MW, Sviglin H, Carpenter M. Impact of ethnicity on outcome in pancreatic carcinoma. JOP. 2005;6:264–54.

36.

Shaib YH, Davila JA, El-Serag HB. The epidemiology of pancreatic cancer in the United States: changes below the surface. Aliment Pharmacol Ther. 2006;24:87–94.PubMed

37.

Silverman DT, Hoover RN, Brown LM, et al. Why do Black Americans have a higher risk of pancreatic cancer than White Americans? Epidemiology. 2003;14:45–54.PubMed

38.

Singal V, Singal AK, Kuo Y-F. Racial disparities in treatment for pancreatic cancer and impact on survival: a population-based analysis. J Cancer Res Clin Oncol. 2012;138:715–722.PubMed

39.

Worni M, Guller U, White RR, et al. Modest improvement in overall survival for patients with metastatic pancreatic cancer. Pancreas. 2013;42:1157–1163.PubMed

40.

Wray CJ, Castro-Echeverry E, Silberfein EJ, et al. A multi-institutional study of pancreatic cancer in Harris County, Texas: race predicts treatment and survival. Ann Surg Oncol. 2012;19:2776–2781.PubMed

41.

Zell JA, Rhee JM, Ziogas A, et al. Race, socioeconomic status, treatment, and survival time among pancreatic cancer cases in California. Cancer Epidemiol Biomark Prev. 2007;16:546–552.

42.

Zhang J, Dhakal I, Yan H, et al. Trends in pancreatic cancer incidence in nine SEER cancer registries, 1973–2002. Ann Oncol. 2007;18:1268–1279.PubMed

43.

Zhou J, Enewold L, Stojadinovic A, et al. Incidence rates of exocrine and endocrine pancreatic cancers in the United States. Cancer Causes Control. 2010;21:853–861.PubMed

44.

Ah-Tye PJ. Pancreatitis in remote Australia: an indigenous perspective. Aust J Rural Health. 2001;9:134–137.PubMed

45.

Akhtar AJ, Shaheen M. Extrapancreatic manifestations of acute pancreatitis in African-American and Hispanic patients. Pancreas. 2004;29:291–297.PubMed

46.

Anderson F, Thomson SR, Clarke DL, et al. Dyslipidaemic pancreatitis clinical assessment and analysis of disease severity and outcomes. Pancreatology. 2009;9:252–257.PubMed

47.

Burge MR, Gabaldon-Bates J. The role of ethnicity in post-pancreatitis diabetes mellitus. Diabetes Technol. Ther. 2003;5:183–188.PubMed

48.

Buscaglia JM, Kapoor S, Jagannath SB, et al. Disparities in demographics among patients with pancreatitis-related mortality. JOP. 2009;10:174–180.PubMed

49.

Chwistek M, Roberts I, Amoateng-Adjepong Y. Gallstone pancreatitis: a community teaching hospital experience. J Clin Gastroenterol. 2001;33:41–44.PubMed

50.

Fagenholz PJ, Fernández-del Castillo C, Harris NS, et al. National study of United States emergency department visits for acute pancreatitis, 1993–2003. BMC Emerg Med. 2007;7:1.PubMedPubMedCentral

51.

Frey CF, Zhou H, Harvey DJ, et al. The incidence and case-fatality rates of acute biliary, alcoholic, and idiopathic pancreatitis in California, 1994–2001. Pancreas. 2006;33:336–344.PubMed

52.

Ho U-C, Mu C-F, Hsu C-Y. Ethnic differences in risk factors of acute pancreatitis. Ethn Health. 2016;23:321–328.PubMed

53.

Kandasami P, Harunarashid H, Kaur H. Acute pancreatitis in a multi-ethnic population. Singap Med J. 2002;43:284–288.

54.

Setiawan VW, Pandol SJ, Porcel J, et al. Dietary factors reduce risk of acute pancreatitis in a large multiethnic cohort. Clin Gastroenterol Hepatol. 2017;15:257–265.PubMed

55.

Shaheen MA, Akhtar AJ. Organ failure associated with acute pancreatitis in African-American and Hispanic patients. J Natl Med Assoc. 2007;99:1402–1406.PubMedPubMedCentral

56.

Yadav D, Muddana V, O’connell M. Hospitalizations for chronic pancreatitis in Allegheny County, Pennsylvania, USA. Pancreatology. 2011;11:546–552.PubMedPubMedCentral

57.

Yaghoubian A, de Virgilio C, El-Masry M, et al. Gallstone pancreatitis: a benign disease in Hispanics. Am Surg. 2007;73:1071–1074.PubMed

58.

Laffan TA, Horton KM, Klein AP, et al. Prevalence of unsuspected pancreatic cysts on MDCT. Am J Roentgenol. 2008;191:802–807.

59.

Petrov MS, Windsor JA, Lévy P. New international classification of acute pancreatitis: more than just 4 categories of severity. Pancreas. 2013;42:389–391.PubMed

60.

Mehta KM, Yeo GW. Systematic review of dementia prevalence and incidence in United States race/ethnic populations. Alzheimer’s Dement. 2017;13:72–83.

61.

Brancati FL, Kao WHL, Folsom AR, et al. Incident type 2 diabetes mellitus in African American and White adults. JAMA. 2000;283:2253.PubMed

62.

Mensah GA, Mokdad AH, Ford ES, et al. State of disparities in cardiovascular health in the United States. Circulation. 2005;111:1233–1241.PubMed

63.

Shaw JJ, Shah SA. Rising incidence and demographics of hepatocellular carcinoma in the USA: what does it mean? Expert Rev Gastroenterol Hepatol. 2011;5:365–370.PubMed

64.

Alsamarrai A, Das SLM, Windsor JA, et al. Factors that affect risk for pancreatic disease in the general population: a systematic review and meta-analysis of prospective cohort studies. Clin Gastroenterol Hepatol. 2014;12:1635–1644.PubMed

65.

Greer JB, Whitcomb DC. Role of BRCA1 and BRCA2 mutations in pancreatic cancer. Gut. 2007;56:601–605.PubMed

66.

Grover S, Syngal S. Hereditary pancreatic cancer. Gastroenterology. 2010;139:1076–1080-2.

67.

Mittal K, Ogden A, Reid MD, et al. Amplified centrosomes may underlie aggressive disease course in pancreatic ductal adenocarcinoma. Cell Cycle. 2015;14:2798–2809.PubMedPubMedCentral

68.

Petrov MS. Harnessing analytic morphomics for early detection of pancreatic cancer. Pancreas. 2018;47:1051–1054.

69.

LaRusch J, Whitcomb DC. Genetics of pancreatitis. Curr Opin Gastroenterol. 2011;27:467–474.PubMedPubMedCentral

70.

WHO|Health of indigenous peoples. WHO [Internet]. 2016 [cited 2017 Nov 9]; Available from: http://www.who.int/mediacentre/factsheets/fs326/en/.

71.

Gracey M, King M. Indigenous health part 1: determinants and disease patterns. Lancet. 2009;374:65–75.PubMed

72.

Eibl G, Cruz-Monserrate Z, Korc M, et al. Diabetes mellitus and obesity as risk factors for pancreatic cancer. J Acad Nutr Diet. 2018;118:555–567.PubMed

73.

Glover M, Kira A, Cowie N, et al. Health consequences of tobacco use for Maori–cessation essential for reducing inequalities in health. N Z Med J. 2013;126:60–73.PubMed

74.

Maclennan B, Kypri K, Connor J, et al. New Zealand’s new alcohol laws: protocol for a mixed-methods evaluation. BMC Public Health. 2015;16:29.

75.

Singh RG, Pendharkar SA, Cervantes A, et al. Abdominal obesity and insulin resistance after an episode of acute pancreatitis. Dig Liver Dis. 2018; [Epub ahead of print].

76.

Busfield F, Duffy DL, Kesting JB, et al. A genomewide search for type 2 diabetes-susceptibility genes in indigenous Australians. Am J Hum Genet. 2002;70:349–357.PubMed

77.

Poa NR, Cooper GJS, Edgar PF. Amylin gene promoter mutations predispose to type 2 diabetes in New Zealand Maori. Diabetologia. 2003;46:574–578.PubMed

78.

Cervantes A, Singh RG, Pendharkar SA, Bharmal SH, Petrov MS. Profile of gut hormones, pancreatic hormones and pro-inflammatory cytokines in New Zealand Maori. Gastroenterol Res. 2018;11:280–289.

79.

Shen H-N, Yang C-C, Chang Y-H, et al. Risk of diabetes mellitus after first-attack acute pancreatitis: a national population-based study. Am J Gastroenterol. 2015;110:1698–1706.PubMed

80.

Singh RG, Nguyen NN, DeSouza SV, Pendharkar SA, Petrov MS. Comprehensive analysis of body composition and insulin traits associated with intra-pancreatic fat deposition in health and new-onset prediabetes/diabetes after acute pancreatitis. Diabetes Obes Metab. 2018. https://doi.org/10.1111/dom.13523.CrossRefPubMed

81.

Yoon K-H, Lee J-H, Kim J-W, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006;368:1681–1688.PubMed

82.

Pardhan S, Mahomed I. Knowledge, self-help and socioeconomic factors in South Asian and Caucasian diabetic patients. Eye. 2004;18:509–513.PubMed

83.

Marriott L, Sim D. Indicators of inequality for Maori and Pacific people. J N Z Stud. 2015;20:24.

84.

DeSouza SV, Singh RG, Yoon HD, et al. Pancreas volume in health and disease: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2018;12:757–766.PubMed

85.

Petrov MS. Diabetes of the exocrine pancreas: American Diabetes Association-compliant lexicon. Pancreatology. 2017;17:523–526.PubMed

86.

Jivanji CJ, Asrani VM, Windsor JA, Petrov MS. New onset diabetes after acute and critical illness: a systematic review. Mayo Clin Proc. 2017;92:762–773.PubMed

Title: African-Americans and Indigenous Peoples Have Increased Burden of Diseases of the Exocrine Pancreas: A Systematic Review and Meta-Analysis
Authors: Aya Cervantes
Ellen K. Waymouth
Maxim S. Petrov
Publication date: 01-01-2019
Publisher: Springer US
Published in: Digestive Diseases and Sciences / Issue 1/2019
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-018-5291-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

How Dye May Prevent Dying from Cancer: Perceiving Imperceptible Dysplasia in Inflammatory Bowel Disease

CircScd1 Promotes Fatty Liver Disease via the Janus Kinase 2/Signal Transducer and Activator of Transcription 5 Pathway

Ultrasonographic Nonalcoholic Fatty Pancreas Is Associated with Advanced Fibrosis in NAFLD: A Retrospective Analysis

Declining Rates of Referral for Irritable Bowel Syndrome Without Constipation at a Tertiary Care Center

Resveratrol Improves Recovery and Survival of Diet-Induced Obese Mice Undergoing Extended Major (80%) Hepatectomy

Dabigatran Reduces Liver Fibrosis in Thioacetamide-Injured Rats

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials